Compare ALLO & GROY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ALLO | GROY |
|---|---|---|
| Founded | 2017 | 2020 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 707.6M | 618.6M |
| IPO Year | 2018 | 2020 |
| Metric | ALLO | GROY |
|---|---|---|
| Price | $1.96 | $2.68 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 15 | 5 |
| Target Price | ★ $8.35 | $5.90 |
| AVG Volume (30 Days) | ★ 7.8M | 1.8M |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 34.09 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $145.80 |
| Revenue Next Year | $142,416.42 | $60.03 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.99 | $2.45 |
| 52 Week High | $4.46 | $5.45 |
| Indicator | ALLO | GROY |
|---|---|---|
| Relative Strength Index (RSI) | 44.13 | 43.52 |
| Support Level | $1.56 | $2.45 |
| Resistance Level | $1.92 | $2.72 |
| Average True Range (ATR) | 0.12 | 0.08 |
| MACD | -0.01 | 0.02 |
| Stochastic Oscillator | 40.82 | 56.60 |
Allogene Therapeutics Inc is a clinical stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. Its pipeline includes "off-the-shelf" T cell candidates designed to target cancer cells or eliminate autoreactive cells in patients with autoimmune disorders. Its three core programs are: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID) and Renal Cell Carcinoma (RCC).
Gold Royalty Corp is principally engaged in acquiring gold-focused royalties, streaming, and similar interests. It is a gold-focused royalty company offering creative financing solutions to the metals and mining industry. The Company operates in Bosnia and Herzegovina, Canada, which generates maximum revenue, the USA, Brazil, and Mexico.